Great Valley Advisor Group Inc. Trims Position in Moderna, Inc. (NASDAQ:MRNA)

Great Valley Advisor Group Inc. decreased its stake in shares of Moderna, Inc. (NASDAQ:MRNAFree Report) by 4.7% in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 8,294 shares of the company’s stock after selling 407 shares during the period. Great Valley Advisor Group Inc.’s holdings in Moderna were worth $857,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently bought and sold shares of the stock. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. increased its position in Moderna by 9.2% during the third quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 363,453 shares of the company’s stock worth $37,541,000 after purchasing an additional 30,619 shares during the last quarter. Harvest Fund Management Co. Ltd increased its position in Moderna by 58.9% during the third quarter. Harvest Fund Management Co. Ltd now owns 3,031 shares of the company’s stock worth $313,000 after purchasing an additional 1,123 shares during the last quarter. Reik & CO. LLC increased its position in shares of Moderna by 11.7% in the third quarter. Reik & CO. LLC now owns 4,780 shares of the company’s stock worth $494,000 after acquiring an additional 500 shares in the last quarter. Wealthspire Advisors LLC increased its position in shares of Moderna by 88.7% in the third quarter. Wealthspire Advisors LLC now owns 3,289 shares of the company’s stock worth $340,000 after acquiring an additional 1,546 shares in the last quarter. Finally, Privium Fund Management B.V. increased its position in shares of Moderna by 43.6% in the third quarter. Privium Fund Management B.V. now owns 43,861 shares of the company’s stock worth $4,530,000 after acquiring an additional 13,310 shares in the last quarter. Institutional investors and hedge funds own 64.51% of the company’s stock.

Insider Activity at Moderna

In related news, insider Shannon Thyme Klinger sold 563 shares of Moderna stock in a transaction dated Friday, December 8th. The shares were sold at an average price of $79.09, for a total value of $44,527.67. Following the sale, the insider now directly owns 7,912 shares in the company, valued at approximately $625,760.08. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. In other Moderna news, insider Shannon Thyme Klinger sold 563 shares of the business’s stock in a transaction dated Friday, December 8th. The shares were sold at an average price of $79.09, for a total transaction of $44,527.67. Following the sale, the insider now directly owns 7,912 shares in the company, valued at approximately $625,760.08. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO James M. Mock sold 772 shares of the business’s stock in a transaction dated Monday, January 8th. The stock was sold at an average price of $109.75, for a total transaction of $84,727.00. Following the sale, the chief financial officer now owns 3,632 shares in the company, valued at $398,612. The disclosure for this sale can be found here. Insiders have sold a total of 106,899 shares of company stock worth $10,732,838 in the last ninety days. 15.70% of the stock is owned by insiders.

Wall Street Analyst Weigh In

MRNA has been the subject of several recent research reports. Royal Bank of Canada reissued an “outperform” rating and issued a $125.00 price objective on shares of Moderna in a research report on Friday, January 12th. Canaccord Genuity Group initiated coverage on shares of Moderna in a research report on Wednesday, November 29th. They issued a “hold” rating and a $82.00 price objective for the company. TheStreet lowered shares of Moderna from a “c” rating to a “d” rating in a research report on Thursday, November 2nd. HSBC raised shares of Moderna from a “reduce” rating to a “hold” rating and dropped their price objective for the stock from $89.00 to $69.00 in a research report on Friday, November 3rd. Finally, The Goldman Sachs Group lowered their price target on shares of Moderna from $269.00 to $231.00 and set a “buy” rating for the company in a report on Friday, November 3rd. Three investment analysts have rated the stock with a sell rating, nine have issued a hold rating and five have assigned a buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Hold” and an average target price of $123.96.

Get Our Latest Analysis on MRNA

Moderna Trading Down 2.3 %

Moderna stock opened at $102.47 on Wednesday. The company has a market cap of $39.07 billion, a P/E ratio of -10.96 and a beta of 1.66. The firm’s 50-day moving average is $93.70 and its 200-day moving average is $97.33. Moderna, Inc. has a 1 year low of $62.55 and a 1 year high of $180.21. The company has a debt-to-equity ratio of 0.04, a quick ratio of 2.35 and a current ratio of 2.46.

Moderna (NASDAQ:MRNAGet Free Report) last issued its quarterly earnings data on Thursday, November 2nd. The company reported ($1.39) earnings per share for the quarter, beating the consensus estimate of ($2.01) by $0.62. The firm had revenue of $1.83 billion for the quarter, compared to the consensus estimate of $1.37 billion. Moderna had a negative net margin of 38.00% and a negative return on equity of 2.14%. On average, equities analysts expect that Moderna, Inc. will post -5.39 earnings per share for the current year.

About Moderna

(Free Report)

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella-zoster virus, and human immunodeficiency virus vaccines; and public health vaccines consists of Zika and Nipah vaccines.

Further Reading

Institutional Ownership by Quarter for Moderna (NASDAQ:MRNA)

Receive News & Ratings for Moderna Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Moderna and related companies with MarketBeat.com's FREE daily email newsletter.